Bear Stearns Downgrades Momenta Pharmaceuticals (MNTA) to Peer Perform
More News related to MNTA
- Momenta Pharmaceuticals (MNTA) March put volatility elevated at 131
- Momenta Pharma (MNTA) Posts Q3 Loss of $0.38, Tops by 2c
- Momenta Pharmaceuticals (MNTA) Tops Q3 EPS by 2c; Revs Light
- Momenta Pharmaceuticals Reports Financial Results for the Third Quarter of 2009
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Downgrades
- Standpoint Research Downgraded Deckers Outdoor (DECK) to Hold
- BGB Securities Downgrades Helmerich & Payne (HP) to Sell
- Sidoti & Co Downgrades Waste Services (WSII) to Neutral
- William Blair Downgrades Strayer (STRA), ITT (ESI) to Market Perform
- D.A. Davidson Downgrades Rocky Brands (RCKY) to Underperform
Bear Stearns downgrades Momenta Pharmaceuticals (Nasdaq: MNTA) from Outperform to Peer Perform.
Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural analysis of complex mixture drugs. [BCS]
Related Categories
DowngradesStocks Mentioned
-0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
